JC Xu, M.D., Ph.D., is the Chief Scientific Officer of Adagene. Dr. Xu has more than 20 years of experience in oncology drug discovery and development and more than 4 years of experience in business development, strategy, and operations in the U.S. biopharmaceutical industry.

Prior to joining Adagene, Dr. Xu was head of R&ED China Strategy at Celgene (now Bristol Myers Squibb). Prior to that, Dr. Xu was Director of Strategy & Operations at Celgene Quanticel Research and Director of Biology at Quanticel Pharmaceuticals. She was instrumental in the successful acquisition of Quanticel by Celgene. Prior to Quanticel, Dr. Xu worked in leadership roles at a number of biopharmaceutical companies, both large and small, including Pfizer, Amgen, and Corixa.

Dr. Xu received her M.D. from Beijing Medical University (now Peking University Health Science Center) and her Ph.D. in immunology from University of Alabama at Birmingham. She completed her post-doctoral training at DNAX Research Institute (now Merck Palo Alto). She is an inventor of more than 120 issued and pending patents and has published more than 50 articles in peer-reviewed journals.

Raymond Tam Man Kin (“Mr. Tam”) is the Chief Financial Officer of Adagene. He has over 20 years of management experience in finance and banking across Asia Pacific.

Prior to Adagene, Mr. Tam served as Chief Financial Officer of different corporations including AgenTus Therapeutics, Inc., Beijing Gas Blue Sky Holdings Limited (a company listed on the Stock Exchange of Hong Kong), and China Regenerative Medicine International Limited (a company listed on the Stock Exchange of Hong Kong). Mr. Tam also served as Project Director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited, both of which are Australian mining companies. Further, he held various management positions with J.P. Morgan and HSBC from 1999 to 2010.

Mr. Tam obtained an Executive Master of Business Administration degree from the University of Western Ontario in Canada in 2005, a Master of Practising Accounting degree from the Monash University in Australia in 2001 and a Bachelor of Civil & Resources Engineering (with First Class Honors) degree from the University of Auckland in New Zealand in 1998.

Felix (Fangyong) Du, Ph.D., is the Chief Technology Officer of Adagene. Dr. Du has over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles in world-renowned scientific journals such as Nature and Science. His discoveries were featured on the cover of Nature and critically reviewed with high praise by prominent scientists in the field.

Before joining Adagene, Dr. Du worked at Affomix, a biotech startup by Yale professors that specializes in high throughput discovery of antibodies against human proteome. He created an innovative technology platform for high throughput preparation and oriented presentation of antigens. After Affomix was acquired by Illumina Inc., Dr. Du continued to develop new technologies in protein and nucleic acid chemistry.

Dr. Du completed his postdoctoral research with Dr. Jorge Galan at Yale University, received his Ph.D. under the guidance of Dr. Alex Varshavsky at the California Institute of Technology, and obtained his B.S. and M.S. from Peking University.

Hua Gong, M.D., Ph.D., is the Chief Operating Officer and Head of Clinical Development and Precision Medicine at Adagene. She has more than 20 years of experience in drug discovery and development, particularly in personalized medicine. Dr. Gong joined Adagene from Novartis Navigate Biopharma where she served as Senior Director, Head of Genomics Biomarker Department. She directly contributed to the U.S. Food and Drug Administration approvals of seven oncology drugs since 2013: Tabrecta™ (capmatinib), Piqray® (alpelisib), Tafinlar® (dabrafenib) + Mekinist® (trametinib) for NSCLC, Kisqali® (ribociclib) , Kymriah® (tisagenlecleucel) and Zykadia® (ceritinib).

Prior to Novartis, she was Executive Director of IVD & CDx at Premier Research Group, where she effectively enabled oncology development programs of their pharmaceutical partners by providing precision medicine solutions. At Prometheus Therapeutics & Diagnostics, Dr. Gong was Associate Director of the Clinical Development Department, where she was responsible for overseeing multiple clinical studies. She successfully contributed to the expansion of Proleukin clinical applications. Additionally, Dr. Gong worked at Pfizer for over 10 years in a variety of positions of increasing responsibility. In her last position at Pfizer, Dr. Gong managed a multi-disciplinary team including in-vitro/vivo biology, PDM, drug safety and biomarker research groups. She was a key contributor to two drugs that entered clinical development.

Dr. Gong received her medical training from An Hui Medical University, her M.S. from Sun Yat-Sen University of Medical Sciences and her Ph.D. in cancer biology from Wayne State University.

Mr. Peter Luo is our Co-Founder and has served as our Chief Executive Officer since November 2011 and Chairman of the Board of the Directors since February 2018. Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor (Nasdaq: XNCR) from July 1998 to August 2000. In September 2000, Dr. Luo founded Abmaxis Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May 2006, Dr. Luo led the acquisition of Abmaxis Inc. by Merck & Co. (NYSE: MRK), after which Dr. Luo served as a director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck & Co. Throughout his career, Dr. Luo also led the business development efforts in connection with collaborations and strategic partnerships with multiple global partners. Dr. Luo received his bachelor’s degree in applied chemistry in technical physics from Peking University in 1986, master’s degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989, and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr. Luo also completed his postdoctoral research in protein folding at Stanford University in 1998.